In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2506-2510

  Solapure, Suresh ^a   Dinesh, Neela ^a   Shandil, Radha ^a   Ramachandran, Vasanthi ^a   Sharma, Sreevalli ^a   Bhattacharjee, Deepa ^a   Ganguly, Samit ^a   Reddy, Jitendar ^a   Ahuja, Vijaykamal ^a   Panduga, Vijender ^a   Parab, Manish ^a   Vishwas, K G ^a   Kumar, Naveen ^a   Balganesh, Meenakshi ^a   Balasubramanian, V ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFALORIDINE; CEFIXIME; CEFOTAXIME; CEFPODOXIME; CLAVULANIC ACID; CLAVULANIC ACID PLUS MEROPENEM; FROPENEM; IMIPENEM; ISONIAZID; MEROPENEM; PENICILLIN G; PIPERACILLIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CLAVULANIC ACID; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; STREPTOMYCIN; THIENAMYCINS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84877867986     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00023-13     Document Type: Article

References (23)

1. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA. 2007. Comparative review of the carbapenems. Drugs 67:1027-1052.
2. Hugonnet JE, Blanchard JS. 2007. Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. Biochemistry 46: 11998-12004.
3. Nampoothiri KM, Rubex R, Patel AK, Narayanan SS, Krishna S, Das SM, Pandey A. 2008. Molecular cloning, overexpression and biochemical characterization of hypothetical beta-lactamases of Mycobacterium tuberculosis H37Rv. J. Appl. Microbiol. 105:59-67.
4. Tremblay LW, Hugonnet JE, Blanchard JS. 2008. Structure of the covalent adduct formed between Mycobacterium tuberculosis beta-lactamase and clavulanate. Biochemistry 47:5312-5316.
5. Harrison MP, Moss SR, Featherstone A, Fowkes AG, Sanders AM, Case DE. 1989. The disposition and metabolism of meropenem in laboratory animals and man. J. Antimicrob. Chemother. 24(Suppl. A):265-277.
6. Novelli A, Mazzei T, Meli E, Conti S, Fallani S, Periti P. 1996. Clinical pharmacokinetics of meropenem after the first and tenth intramuscular administration. J. Antimicrob. Chemother. 37:775-781.
7. Dauby N, Muylle I, Mouchet F, Sergysels R, Payen MC. 2011. Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis. Pediatr. Infect. Dis. J. 30:812-813.
8. Payen MC, De Wit S, Martin C, Sergysels R, Muylle I, Van Laethem Y, Clumeck N. 2012. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 16:558-560.
9. England K, Boshoff HI, Arora K, Weiner D, Dayao E, Schimel D, Via LE, Barry CE. 2012. Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrob. Agents Chemother. 56: 3384-3387.
10. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE, III, Blanchard JS. 2009. Meropenem-clavulanate is effective against extensively drugresistant Mycobacterium tuberculosis. Science 323:1215-1218.
11. Wayne LG, Hayes LG. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64:2062-2069.
12. Sala C, Dhar N, Hartkoorn RC, Zhang M, Ha YH, Schneider P, Cole ST. 2010. Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 54:4150-4158.
13. Franzblau SG, Witzig RS, McLaughlin JC, Torres P, Madico G, Hernandez A, Degnan MT, Cook MB, Quenzer VK, Ferguson RM, Gilman RH. 1998. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J. Clin. Microbiol. 36:362-366.
14. Reddy J, Madishetti S, Vachaspati PR. 2012. Fast mouse PK (Fast PK): A rapid screening method to increase pharmacokinetic throughput in preclinical drug discovery. Eur. J. Pharm. Sci. 47:444-450.
15. Balasubramanian V, Solapure S, Gaonkar S, Mahesh Kumar KN, Shandil RK, Deshpande A, Kumar N, Vishwas KG, Panduga V, Reddy J, Ganguly S, Louie A, Drusano GL. 2012. Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model. Antimicrob. Agents Chemother. 56:3054-3057.
16. Dinesh N, Sharma S, Balganesh M. 2013. Involvement of efflux pumps in the resistance to peptidoglycan synthesis inhibitors in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 57:1941-1943.
17. Zhang M, Sala C, Hartkoorn RC, Dhar N, Mendoza-Losana A, Cole ST. 2012. SS18b: A drug discovery tool for latent tuberculosis. Antimicrob. Agents Chemother. 56:5782-5789.
18. Craig WA. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. North Am. 17:479-501.
19. Munoz-Elias EJ, Timm J, Botha T, Chan WT, Gomez JE, McKinney JD. 2005. Replication dynamics of Mycobacterium tuberculosis in chronically infected mice. Infect. Immun. 73:546-551.
20. Gill WP, Harik NS, Whiddon MR, Liao RP, Mittler JE, Sherman DR. 2009. A replication clock for Mycobacterium tuberculosis. Nat. Med. 15: 211-214.
21. Dubee V, Triboulet S, Mainardi JL, Etheve-Quelquejeu M, Gutmann L, Marie A, Dubost L, Hugonnet JE, Arthur M. 2012. Inactivation of Mycobacterium tuberculosis L,D-transpeptidase LdtMt1 by carbapenems and cephalosporins. Antimicrob. Agents Chemother. 56:4189-4195.
22. Gupta R, Lavollay M, Mainardi J-L, Arthur M, Bishai WR, Lamichhane G. 2010. The Mycobacterium tuberculosis gene, ldtMt2, encodes a nonclassical transpeptidase required for virulence and resistance to amoxicillin. Nat. Med. 16:466-469.
23. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. 2004. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 190:1642-1651.